Structure Therapeutics Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Thomas R CarperSenate · D · DE |
GPCRStructure Therapeutics Inc. · Stock |
Sale $1,001 - $15,000 |
Nov 2, 2023 | Oct 4, 2023 | Filing ↗ |
Whale Activity
- Increased50
- New23
- Held34
- Decreased57
- Closed44
- No prior filing8
| Filer | Shares | Value | Change |
|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 9.8M | $305.3M | increased |
| FMR LLC | 9.4M | $292.5M | increased |
| Avoro Capital Advisors LLC | 6.6M | $205.0M | held |
| Janus Henderson Group Ltd. | 5.1M | $158.5M | — |
| Deep Track Capital, LP | 5.0M | $156.3M | increased |
| MORGAN STANLEY | 2.8M | $88.1M | increased |
| BVF INC/IL | 2.7M | $84.2M | decreased |
| RTW INVESTMENTS, LP | 2.3M | $71.4M | increased |
| BAKER BROS. ADVISORS LP | 1.4M | $44.8M | held |
| ORBIMED ADVISORS LLC | 1.3M | $41.6M | decreased |
| Paradigm Biocapital Advisors LP | 1.3M | $40.6M | new |
| PRINCIPAL FINANCIAL GROUP INC | 1.3M | $39.6M | — |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Conversion | −12.0K | $0.00 | $0 | Sep 21, 2026 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Tax withholding | −10.6K | $11.67 | $124K | Sep 18, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −17.8K | $0.00 | $0 | Sep 1, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +17.8K | $0.34 | $6K | Sep 1, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −11.8K | $0.00 | $0 | Aug 18, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +11.8K | $0.34 | $4K | Aug 18, 2026 | Form 4 ↗ |
| Berrios John JosephChief Commercial Officer | Grant / award | +140.8K | $0.00 | $0 | Aug 6, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −11.8K | $0.00 | $0 | Aug 4, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +11.8K | $0.34 | $4K | Aug 4, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −23.6K | $0.00 | $0 | Jul 14, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +23.6K | $0.34 | $8K | Jul 14, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Conversion | −23.6K | $0.00 | $0 | Jun 25, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | +23.6K | $0.34 | $8K | Jun 25, 2026 | Form 4 ↗ |
| Lang MatthewCOO & GC | Grant / award | +184.6K | $0.00 | $0 | Apr 15, 2026 | Form 4 ↗ |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | Grant / award | +75.9K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Ma YingliCHIEF TECHNOLOGY OFFICER | Grant / award | +32.5K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Lin XichenCHIEF SCIENTIFIC OFFICER | Grant / award | +43.4K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Yoon JunCHIEF FINANCIAL OFFICER | Grant / award | +104.1K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Hall AshleyChief Development Officer | Grant / award | +47.7K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
| Stevens Raymond CCHIEF EXECUTIVE OFFICER · Director | Grant / award | +260.2K | $0.00 | $0 | Mar 19, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Heritage Fund American Century Mutual Funds, Inc. | 967.4K | $46.5M | 0.87% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund Fidelity Advisor Series I | 733.5K | $33.7M | 0.10% | Aug 31, 2026 |
| Global Emerging Markets Fund Principal Funds, Inc | 625.8K | $30.1M | 0.40% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 549.4K | $29.5M | 0.51% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 527.9K | $25.4M | 1.15% | Jul 31, 2026 |
| Janus Henderson Triton Fund Janus Investment Fund | 467.1K | $25.1M | 0.42% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 542.0K | $24.9M | 0.40% | Aug 31, 2026 |
| Select Health Care Portfolio Fidelity Select Portfolios | 500.0K | $23.0M | 0.34% | Aug 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 419.4K | $22.5M | 0.19% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 414.3K | $22.2M | 0.24% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list GPCR's shares (CUSIP 86366E106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- David KroinSCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
Nov 16, 2026 · ↗ - Deep Track Biotechnology Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
Nov 16, 2026 · ↗ - Deep Track Capital, LPSCHEDULE 13G/A · passive (13G) · 15.0M shares7.2%
Nov 16, 2026 · ↗ - Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares12.8%
Nov 16, 2026 · ↗ - Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
Nov 16, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
Nov 16, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 29.3M shares13.6%
Nov 16, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 32.1M shares15.0%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 32.1M shares15.0%
Nov 5, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 28.2M shares13.2%
Aug 6, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Structure Therapeutics Inc. as the client.
Government Contracts
No federal contract awards found for Structure Therapeutics Inc..
U.S. Patents
No USPTO patent applications found for Structure Therapeutics Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating income | -$176.6M | -$158.2M | -$102.8M | -$52.6M |
| Net income | -$141.2M | -$122.5M | -$89.6M | -$51.3M |
| Diluted EPS | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M | -$46.1M |
| Cash and equivalents | $799.6M | $169.5M | $129.8M | $26.1M |
| Total assets | $1.58B | $903.3M | $482.0M | $97.8M |
| Total liabilities | $67.5M | $38.5M | $29.1M | $13.0M |
| Shareholders' equity | $1.52B | $864.8M | $453.0M | -$115.1M |
As Structure Therapeutics Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in GPCR's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 18, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.02, 8.01, 9.01Material agreement · Results of operations · Other eventsMay 7, 2026
EDGAR ↗

